“…Evidence suggest that noncoding variants identified by GWASs may be involved in transcriptional mechanisms (Maurano & Stamatoyannopoulos, ; Lucas D. Ward & Kellis, ) and thus co‐localizing the noncoding variants with expression quantitative trait loci (eQTL) could provide insights into gene expression regulation (Westra et al, ) and biological basis for disease associations (Cookson, Liang, Abecasis, Moffatt, & Lathrop, ; Degner et al, ). Such integrative studies have been performed successfully in multiple psychiatric disorders (Cross‐Disorder Group of the Psychiatric Genomics Consortium, ), including schizophrenia (Luo et al, ; Yang, Li, et al, ), autism spectrum disorder (Wang et al, ), attention deficit‐hyperactivity disorder (Yang, Chang, et al, ), bipolar disorder (Li et al, ), and major depressive disorder (Huo et al, ). Integrating GWAS signals of DD with eQTLs derived from human brain tissues will be useful to identify any functional variants.…”